VYGR - ボイジャ―・セラピュ―ティクス (Voyager Therapeutics Inc.) ボイジャ―・セラピュ―ティクス



symbol VYGR
会社名 Voyager Therapeutics Inc (ボイジャ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ボイジャー・セラピューティクス(Voyager Therapeutics Inc.)は臨床段階の遺伝子治療会社である。同社は中枢神経系(CNS)疾患患者向け治療法の開発を行う。同社のパイプラインは進行性パーキンソン病、筋萎縮性側索硬化症(ALS)の単一遺伝子病、ハンチントン病、フリードライヒの運動失調、前頭側頭型認知症・アルツハイマー病及び慢性疼痛を含むCNS適応症向けプログラムを含む。同社の臨床的製品候補であるVY-AADC01は進行性パーキンソン病の治療向けアデノ随伴ウイルス(AAV)遺伝子治療薬候補である。VY-AADC01は複数のAAV遺伝子治療臨床試験に使用されるAAV2キャプシドと芳香族L-アミノ酸デカルボキシラーゼ(AADC)トランスジーンの発現を駆動するサイトメガロウイルスプロモーターを含む。パイプラインにはVY-SOD101、VY-FXN01、VY-HTT01、VY-TAU01、VY-NAV01を含む。   ボイジャ―・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、中枢神経系の疾患に対する遺伝子治療の開発に従事。特定のタンパク質に焦点を当て、アデノ随伴ウイルス遺伝子治療のアプロ―チにより症状の進行を遅らせることを目的とする。主にパ―キンソン病、脊髄筋萎縮症、ハンチントン舞踏病などの治療に貢献する。本社はマサチュ―セッツ州ケンブリッジ。   Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
本社所在地 75 Sidney Street Cambridge MA 02139 USA
代表者氏名 Mark J. Levin マーク・J.レヴィン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-259-5340
設立年月日 41426
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 89人
url www.voyagertherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vygr
EBITDA EBITDA(百万ドル) -80.64900
終値(lastsale) 16.96
時価総額(marketcap) 550114712.64
時価総額 時価総額(百万ドル) 509.24530
売上高 売上高(百万ドル) 11.01000
企業価値(EV) 企業価値(EV)(百万ドル) 313.12230
当期純利益 当期純利益(百万ドル) -80.64200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Voyager Therapeutics Inc revenues increased 33% to $3.5M. Net loss increased 28% to $45.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $1.8M to $7.9M (expense) General and administrative increase of 45% to $11M (expense).



   Voyager Digital Provides End of Year Business Update  2019/12/04 13:50:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Voyager Digital (Canada) Ltd. (“Voyager” or the “Company”) (CSE:VYGR) (OTCQB:VYGVF) (FRA:UCD2), a licensed crypto-asset broker that provides investors with a turnkey solution to trade crypto-assets, is pleased to provide shareholders with a business and operational update as of November 30, 2019. “We continue to experience tremendous account growth driven by the Voyager App’s availability now for Android, which represents 70% of the mobile market,” said Stephen Ehrlic
   Voyager Therapeutics’ (VYGR) “Buy” Rating Reaffirmed at Cowen  2019/11/08 00:12:42 Modern Readers
Cowen reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Wednesday morning, AnalystRatings.com reports. A number of other research firms also recently weighed in on VYGR. Zacks Investment Research raised shares of Voyager Therapeutics from a hold rating to a buy rating and set a $19.00 […]
   Voyager Digital Vastly Increases its Market by Releasing New Crypto Broker and Trading App for Android  2019/10/28 06:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Voyager Digital (Canada) Ltd. (“Voyager” or the “Company”) (CSE: VYGR) (OTC Pink: VYGVF) (FRA: UCD2), an industry-leading best execution crypto asset broker, today announced its flagship crypto broker and trading app, The Voyager App, is now available on Android. Voyager Digital’s entrance into the Android marketplace is a major milestone in its international expansion. The App is fast, easy to set up and can be downloaded on Google Playstore. It will be powered by Vo
   Voyager Therapeutics (VYGR) Q2 Earnings and Revenues Top Estimates  2019/08/09 12:25:07 Zacks Investment Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 132.95% and 777.85%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Voyager Therapeutics (VYGR) Q2 Earnings Expected to Decline  2019/07/30 14:38:25 Zacks Investment Research
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   3 Gene Therapy Stocks For A Biotech Portfolio  2019-05-20
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma…
   Voyager updates late-stage development of gene therapy VY-AADC for Parkinson's; shares up 2%  2019-01-07
Base on FDA feedback, Voyager Therapeutics ( VYGR +1.8% ) will increase the number of participants in its Phase 3 RESTORE-1 study evaluating gene therapy VY-AADC in Parkinson's disease patients to as many as 100. More news on: Voyager Therapeutics, Healthcare stocks news, Stocks on the m…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ボイジャ―・セラピュ―ティクス VYGR Voyager Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)